List of Excipients in Branded Drug LIDOCAINE VISCOUS

« Back to Dashboard

Generic Drugs Containing LIDOCAINE VISCOUS

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	lidocaine hydrochloride	0054-3500	CARBOXYMETHYLCELLULOSE SODIUM
Hikma Pharmaceuticals USA Inc	lidocaine hydrochloride	0054-3500	METHYLPARABEN
Hikma Pharmaceuticals USA Inc	lidocaine hydrochloride	0054-3500	PROPYLPARABEN
Hikma Pharmaceuticals USA Inc	lidocaine hydrochloride	0054-3500	SACCHARIN SODIUM
Hikma Pharmaceuticals USA Inc	lidocaine hydrochloride	0054-3500	WATER
Pharmaceutical Associates Inc	lidocaine hydrochloride	0121-0903	CARBOXYMETHYLCELLULOSE SODIUM

What are the Most Frequently-Used Excipients in LIDOCAINE VISCOUS?

# Of NDCs	Excipient
6	CARBOXYMETHYLCELLULOSE SODIUM
6	METHYLPARABEN
6	PROPYLPARABEN
6	SACCHARIN SODIUM
5	WATER

Lidocaine Viscous Excipient Strategy, Patent Position, FDA Status, and Commercial Opportunities

Last updated: September 9, 2026

Lidocaine viscous is a mature, prescription oral topical anesthetic. Its commercial differentiation depends less on the active pharmaceutical ingredient and more on excipient control, dosing safety, palatability, viscosity, packaging, and supply reliability. The core opportunity is to improve usability without changing the product’s established pharmacology or creating new systemic exposure risks.

What is lidocaine viscous and how is it regulated?

Lidocaine viscous is generally a 2% lidocaine hydrochloride oral topical solution containing 20 mg/mL of lidocaine hydrochloride. It is used for temporary relief of pain and irritation in the mouth and throat and for reducing gagging during selected procedures, depending on the product label. The solution is intended for topical use and should not be swallowed in large quantities.

The reference product is Xylocaine Viscous 2%, historically associated with AstraZeneca and earlier originator companies. Generic lidocaine hydrochloride oral topical solutions are approved under the FDA abbreviated new drug application pathway.

Attribute	Typical status
Active ingredient	Lidocaine hydrochloride
Common strength	2%, equivalent to 20 mg/mL
Dosage form	Oral topical solution
Route	Oral mucosal topical administration
Regulatory category	Prescription drug
FDA pathway for generics	ANDA
Reference product	Xylocaine Viscous 2%
Primary commercial issue	Safe and acceptable delivery of a high-concentration local anesthetic
Main differentiation tools	Excipients, packaging, taste, viscosity, dosing controls, supply

FDA labeling places material restrictions on use, dose, swallowing, and administration to children. Oral topical lidocaine products have been associated with serious adverse events when excessive amounts are swallowed or used in young children. The FDA specifically warned against using prescription oral viscous lidocaine for teething pain in infants and young children. [1]

What excipients are used in lidocaine viscous formulations?

Lidocaine viscous products commonly use a cellulose-based thickener, humectant, sweetener, flavor system, preservative, pH adjuster, and purified water. The exact formulation varies by manufacturer and product code.

Representative excipient classes

Excipient class	Common examples	Primary function	Commercial importance
Viscosity modifier	Carboxymethylcellulose sodium, hypromellose	Increases residence time and creates a viscous mouthfeel	Central to product performance
Humectant	Glycerin, sorbitol	Improves mouthfeel and reduces drying	Affects sweetness and osmolality
Sweetener	Sodium saccharin, sucralose	Masks lidocaine bitterness	Important for adherence and repeat use
Flavor	Mint, cherry, other proprietary flavors	Reduces bitterness and medicinal taste	Key source of patient differentiation
Preservative	Methylparaben, propylparaben, benzoic acid	Controls microbial growth	Supports multidose packaging
Buffer or pH adjuster	Citric acid, sodium citrate, sodium hydroxide	Controls pH and stability	Influences taste, comfort, and preservative activity
Vehicle	Purified water	Solvent and dosage-form base	Determines microbial and physical stability

Xylocaine Viscous labeling identifies inactive ingredients including carboxymethylcellulose sodium, glycerin, methylparaben, sodium saccharin, flavoring, benzoic acid, and water. Generic products may use different combinations or concentrations, so formulation comparison must be conducted at the product-label and pharmaceutical-equivalence level. [2]

How should the excipient strategy be designed?

The formulation objective is not maximum viscosity. It is controlled mucosal coverage, acceptable taste, physical stability, dose uniformity, and safe handling.

Viscosity modifiers

Carboxymethylcellulose sodium is a common choice because it hydrates in water, has broad pharmaceutical use, and can generate the required viscous texture at relatively low concentrations. Hypromellose is an alternative with different hydration, shear, and mouthfeel characteristics.

The key formulation variables are:

• Apparent viscosity across relevant shear rates.
• Pourability from the commercial container.
• Dose uniformity after storage.
• Sedimentation or phase separation.
• Syringeability if supplied in unit-dose or oral-syringe packaging.
• Residence time on oral mucosa.
• Compatibility with lidocaine hydrochloride and preservatives.

A product that is too thin may provide inadequate mucosal coverage and weak differentiation from standard oral solutions. A product that is too thick may produce dosing variability, poor pourability, unpleasant mouthfeel, and difficulty measuring the intended volume.

Humectants and polyols

Glycerin can improve mouthfeel and reduce the drying sensation caused by an aqueous formulation. It also contributes to sweetness and viscosity. Sorbitol can provide a different sweetness and body profile but may create gastrointestinal concerns if substantial quantities are swallowed.

Polyol selection should account for:

• Osmolality.
• Dental acceptability.
• Gastrointestinal tolerance.
• Compatibility with preservatives.
• Impact on viscosity.
• Taste persistence.

Sweetener systems

Lidocaine has a pronounced bitter taste. Sodium saccharin is widely used because it is potent at low concentrations and stable across many oral formulations. Sucralose can produce a different sweetness profile and may support sugar-free positioning.

Sweetener strategy must manage the delay between initial contact and aftertaste. A formulation that masks the first bitter note but leaves a persistent medicinal aftertaste may perform poorly in patient preference testing.

Potential commercial positions include:

1. Lower-bitterness adult formulation.
2. Sugar-free formulation.
3. Reduced-flavor formulation for patients with taste sensitivity.
4. Institutionally acceptable formulation with limited fragrance and flavor carryover.
5. Unit-dose product with a consistent taste profile across lots.

A pediatric positioning requires particular regulatory and safety discipline. Taste improvement does not remove the risks associated with swallowing lidocaine or administering the product to children outside the approved labeling.

Flavor systems

Flavor is a major product-development variable because lidocaine can be difficult to mask. Mint may provide a stronger counter-note but can increase perceived irritation in some patients. Fruit flavors may improve acceptability but can create a stronger pediatric association, which is commercially attractive but may increase misuse risk.

Flavor selection should be evaluated against:

• Bitter suppression.
• Burning or cooling sensation.
• Compatibility with pH and preservatives.
• Stability over shelf life.
• Patient preference by age and indication.
• Risk of accidental ingestion or use outside the label.

A restrained flavor system may be preferable for hospitals and procedural settings, while a stronger flavor may support retail pharmacy differentiation.

What formulation patents could protect lidocaine viscous products?

A conventional lidocaine viscous formulation is unlikely to have meaningful composition-of-matter patent protection because lidocaine and common excipients are long-established. Commercially relevant protection would more likely involve a narrow formulation, device, packaging, or use claim.

Potential patentable subject matter

Area	Potential claim focus	Relative patent opportunity
Taste masking	Specific sweetener-flavor combination or bitterness reduction	Moderate, but prior-art intensive
Viscosity control	Defined rheology profile using specified polymer concentration	Moderate
Preservative-free formulation	Sterile or microbial-control approach for multidose use	Moderate to high technical burden
Unit-dose delivery	Premeasured cup, sachet, or oral syringe system	Moderate
Dose-limiting packaging	Container closure or dispensing system that restricts volume	Moderate
Sublingual or buccal delivery	Enhanced mucosal residence and controlled release	Moderate
Low-swallow formulation	Localized deposition with reduced gastrointestinal exposure	Potentially significant
Manufacturing method	Order of addition, hydration process, deaeration, or blending	Usually narrow
Method of use	Specific procedural use or defined patient population	Limited and vulnerable to design-around

Patent strength would depend on whether the claims require a meaningful technical result, such as a defined viscosity range, improved stability, reduced microbial risk, or validated taste masking. Broad claims covering "lidocaine, a thickener, a sweetener, and water" would face substantial novelty and obviousness challenges.

What is the Orange Book status of lidocaine viscous?

Lidocaine viscous is generally a legacy generic market rather than an active exclusivity market. The reference product and generic versions are subject to FDA labeling and approval requirements, but the commercial field is not normally protected by a current new chemical entity exclusivity period.

The Orange Book is relevant for identifying listed patents and regulatory exclusivity associated with approved products. For an old lidocaine oral topical solution, the principal commercial barriers are usually regulatory execution, manufacturing quality, supply continuity, and customer preference rather than active Orange Book patent barriers. [3]

Exclusivity or protection category	Relevance to lidocaine viscous
New chemical entity exclusivity	Not expected for lidocaine
Five-year new product exclusivity	Not expected for this legacy product
Three-year clinical investigation exclusivity	Not expected for conventional generic entry
Orphan-drug exclusivity	Not associated with the standard product
Pediatric exclusivity	No general current protection for the conventional product
Patent term extension	Not expected to be commercially relevant
Orange Book patents	Must be checked by product and current listing date
Generic approval pathway	ANDA, subject to reference-product requirements

Because Orange Book listings and approved product records can change, transaction or launch decisions should rely on the current FDA listing and the applicable product-specific labeling. [3]

When does lidocaine viscous lose exclusivity?

Lidocaine viscous has effectively operated as a post-exclusivity product for many years. Lidocaine was discovered and commercialized decades ago, and conventional 2% oral topical solutions do not depend on surviving active-ingredient exclusivity.

The absence of meaningful molecule-level exclusivity does not eliminate commercial barriers. A new entrant still must establish:

• Pharmaceutical equivalence.
• Bioequivalence or the applicable FDA waiver pathway.
• Appropriate chemistry, manufacturing, and controls.
• Stability and preservative effectiveness.
• Container-closure suitability.
• Labeling conformity.
• Manufacturing inspection readiness.
• Reliable supply of lidocaine hydrochloride and critical excipients.

For a conventional ANDA, the central competitive question is usually whether the applicant can obtain approval and maintain acceptable product quality at a sustainable cost.

Are Paragraph IV challenges relevant to lidocaine viscous?

Paragraph IV litigation is generally less central for conventional lidocaine viscous products than for recently approved branded medicines. An ANDA applicant may still certify against listed patents or challenge a listed patent, but the practical significance depends on whether any enforceable Orange Book patent remains associated with the reference product.

The most likely outcomes are:

• Paragraph III certification where a listed patent remains but has not expired.
• Paragraph IV certification where the applicant alleges invalidity, unenforceability, or non-infringement.
• No meaningful patent litigation where no relevant patent is listed.
• Non-patent regulatory competition based on approval timing and manufacturing capacity.

For an improved formulation, a developer may seek separate patent protection. That can create a new litigation profile, particularly if the improved product includes a distinctive preservative system, delivery device, or controlled-release feature.

What FDA regulatory issues affect excipient selection?

FDA review of lidocaine viscous focuses on product quality, labeling, dose control, microbial quality, and safe use. Excipients must be suitable for the route, concentration, and duration of exposure. A common excipient in oral products is not automatically acceptable at every concentration or in every patient population.

Key regulatory controls

Preservative effectiveness

Multidose oral liquids require protection against microbial contamination. Methylparaben, propylparaben, benzoic acid, or related systems may be used depending on pH, concentration, packaging, and formulation composition.

A preservative-free product can be commercially attractive but requires a credible microbial-control strategy. Options include:

• Unit-dose packaging.
• Smaller fill volumes.
• Tamper-evident single-use containers.
• Alternative container systems.
• Validated aseptic processing where justified.
• Formulation pH control and manufacturing hygiene.

Removing parabens without replacing their function can create a material stability and microbiological risk.

pH

pH affects lidocaine ionization, taste, mucosal comfort, preservative performance, and chemical stability. A low-pH formulation may improve preservative activity but can increase sourness or irritation. A higher-pH formulation may improve taste in some systems but reduce preservative effectiveness or alter stability.

The target should be based on measured product performance rather than a single theoretical pH value.

Dose accuracy

Lidocaine viscous carries a meaningful dosing risk because a small volume contains a relatively high active dose. Packaging and dosing accessories are therefore commercial and regulatory design variables.

Potential controls include:

• Calibrated oral syringes.
• Marked dosing cups.
• Unit-dose cups.
• Restricted-volume dispensing closures.
• Child-resistant packaging.
• Clear "do not swallow" or use-specific instructions where consistent with labeling.

Flavor and accidental-use risk

A highly palatable formulation may improve intended use but could increase the likelihood of accidental ingestion. Flavor development must be balanced against the FDA safety history of oral viscous lidocaine.

What commercial opportunities exist for lidocaine viscous?

The strongest opportunities are product improvements that reduce operational friction without changing the established dosage form.

Preservative-free unit-dose products

A preservative-free product in single-use packaging could address concerns about parabens, repeated container opening, and contamination. The tradeoff is higher packaging cost, more material consumption, and potential difficulty competing with low-cost multidose generics.

Target customers include:

• Hospitals.
• Emergency departments.
• Dental offices.
• Ambulatory surgery centers.
• Endoscopy facilities.
• Institutional pharmacies.

Improved dosing systems

A bottle-and-cup presentation is inexpensive but can produce measurement error. An oral syringe or unit-dose cup may support better dose control and reduce spills.

The strongest commercial case exists where the buyer values medication administration accuracy over the lowest acquisition price.

Taste-masked adult formulations

Adult patients often tolerate short-term taste disadvantages poorly, particularly when oral pain already limits eating and drinking. A formulation with reduced bitterness and lower aftertaste could support pharmacy substitution, private-label partnerships, and direct institutional contracts.

The product should not rely on excessive sweetness or child-oriented flavoring. A neutral or mild mint profile may have broader adult and institutional utility.

Lower-volume, higher-residence formulations

A formulation with improved mucosal residence could potentially deliver the intended local effect with a lower administered volume. This would require clinical and regulatory substantiation. The opportunity is technically more valuable than simple flavor reformulation but also carries greater development cost and regulatory risk.

Dental and procedural packaging

Dental and procedural users may value:

• Single-use cups.
• Clearly labeled administration volumes.
• Fast preparation.
• Low spill risk.
• Compact storage.
• Compatible dispensing accessories.
• Mild flavor and limited aerosolization.

A product designed for procedure-room workflow can compete on total cost of use rather than acquisition price alone.

How does lidocaine viscous compare with other oral topical anesthetics?

Lidocaine viscous competes with benzocaine gels, sprays, compounded mouth rinses, and non-anesthetic products. Its principal distinction is the combination of relatively high local anesthetic potency and a viscous aqueous vehicle.

Product category	Main strength	Main weakness	Excipient opportunity
Lidocaine viscous	Broad mucosal coverage and established clinical use	Dosing and swallowing risk; bitter taste	Taste, viscosity, packaging
Benzocaine gel	Familiar consumer format	Methemoglobinemia concern and limited spread	Safer positioning and controlled dosing
Lidocaine spray	Rapid, localized administration	Less uniform coverage and aerosol handling	Metered delivery
Compounded mouth rinse	Customizable formulation	Variable quality, availability, and standardization	Commercial standardized alternatives
Non-anesthetic rinse	Lower anesthetic risk	Less immediate numbing	Comfort, flavor, and adherence

FDA has warned about benzocaine-associated methemoglobinemia, particularly in young children. Lidocaine has its own systemic toxicity and misuse risks, so neither category should be positioned as universally safer without product-specific evidence. [1, 4]

What manufacturing and supply barriers affect lidocaine viscous?

The active ingredient is mature, but manufacturing execution still determines margin and approval risk.

Critical manufacturing variables

• Hydration time of the cellulose polymer.
• Order of excipient addition.
• Prevention of polymer clumping.
• Control of foam and entrained air.
• Uniform dispersion of flavor and preservatives.
• pH adjustment after complete hydration.
• Bulk-hold time.
• Viscosity drift during storage.
• Filling accuracy for viscous liquid.
• Container compatibility and extractables.
• Microbial control during compounding and filling.

The most important process-development issue is often polymer hydration. Incomplete hydration can create lot-to-lot viscosity variation, while excessive shear can alter rheology or introduce air. Flavor oils and other hydrophobic components may require controlled addition or solubilization to maintain uniformity.

Supply-chain exposure exists for pharmaceutical-grade carboxymethylcellulose, flavor components, parabens, specialty packaging, and lidocaine hydrochloride. Dual sourcing is commercially valuable, but changing a critical excipient supplier may require comparability work and stability support.

How strong is the patent estate for lidocaine viscous?

The conventional patent estate is weak relative to newer pharmaceutical products because:

• Lidocaine is an old active ingredient.
• The 2% oral topical solution is a longstanding dosage form.
• Common excipients are widely used.
• Generic approval is established.
• Product differentiation is often incremental.

A stronger patent position may be available for a genuinely improved platform, such as:

1. A defined rheological profile that increases mucosal residence.
2. A preservative-free multidose system with validated microbial protection.
3. A dose-limiting dispensing device.
4. A clinically demonstrated bitterness-reduction system.
5. A low-volume delivery system that maintains local anesthetic effect.
6. A combination of formulation and packaging that reduces accidental ingestion.

Patent claims should be supported by comparative data. Taste preference alone may not establish a strong inventive step unless tied to a specific composition and measurable performance.

What generic launch risks exist for lidocaine viscous?

A generic entrant faces low molecule-level patent risk but meaningful execution risk.

Risk	Likely commercial effect
FDA deficiency related to formulation or controls	Delayed approval
Viscosity variability	Product complaints, dose-uniformity concerns
Preservative failure	Recall or manufacturing disruption
Taste rejection	Weak substitution and low repeat use
Container incompatibility	Stability failure
Lidocaine API shortage	Production interruption
Low price competition	Margin compression
Labeling mismatch	Regulatory delay or enforcement risk
Pediatric misuse concerns	Marketing and labeling restrictions
Excessive packaging cost	Weak pharmacy and institutional economics

The market can support additional suppliers, but a plain generic may face limited margin unless it secures a reliable channel, preferred-packaging position, private-label contract, or differentiated excipient profile.

What revenue exposure and licensing opportunities exist?

Most companies do not publicly disclose revenue for individual lidocaine viscous products. The product is typically embedded within broader local anesthetic, hospital, or generic portfolios. Commercial value therefore depends on channel access and supply reliability rather than on molecule exclusivity.

Licensing and partnership structures

Potential transactions include:

• Private-label supply to pharmacy chains.
• Contract manufacturing for institutional distributors.
• Co-development of unit-dose packaging.
• Licensing of a taste-masking technology.
• Device licensing for dose-controlled dispensing.
• Regional rights for an improved formulation.
• Acquisition of an approved ANDA or manufacturing site.

A formulation patent without manufacturing scale may have limited value. Conversely, an approved product with stable supply and a differentiated container can generate value even with limited patent protection.

What geographic coverage matters?

The United States is attractive because of established prescription demand and the ANDA pathway, but commercial requirements differ by jurisdiction.

Region	Key considerations
United States	FDA approval, labeling, Orange Book status, ANDA competition
European Union	National or centralized regulatory strategy, excipient and packaging requirements
Canada	Health Canada product authorization and bilingual labeling
Japan	Local regulatory requirements and formulation comparability
Emerging markets	Price sensitivity, local registration, supply reliability

Patent protection for a reformulated product must be assessed separately by country. A U.S. formulation patent does not provide equivalent protection in Europe, Canada, or other markets. Device claims may offer broader commercial leverage in some territories, but enforcement and regulatory classification can differ.

Key Takeaways

• Lidocaine viscous is a mature 2% oral topical solution market with little molecule-level exclusivity.
• Excipients are the main route to product differentiation.
• Carboxymethylcellulose sodium, glycerin, sweeteners, flavors, preservatives, and pH adjusters directly affect performance and commercial acceptance.
• The strongest near-term opportunities are preservative-free unit doses, improved dosing systems, adult taste masking, and procedure-focused packaging.
• Conventional formulation claims are likely to be narrow and vulnerable unless supported by comparative technical data.
• FDA safety concerns make dose control, child-resistant packaging, and responsible flavor design central development issues.
• Generic entry risk is driven more by manufacturing, supply, labeling, and price competition than by active pharmaceutical ingredient patents.
• Licensing value is highest where formulation technology is paired with an approved product, differentiated packaging, or reliable manufacturing capacity.

FAQs

Is lidocaine viscous still patent protected?

The conventional lidocaine viscous product is generally a post-exclusivity product. Any current patent risk must be assessed against the specific reference product, Orange Book listing, formulation, and delivery system.

Which excipient most affects lidocaine viscous performance?

The viscosity modifier usually has the greatest effect on product behavior because it controls mucosal residence, pourability, dose uniformity, and mouthfeel. Carboxymethylcellulose sodium and hypromellose are common technical options.

Can a preservative-free lidocaine viscous product be commercialized?

Yes, but the product requires a validated microbial-control strategy. Unit-dose packaging is the most direct approach, while preservative removal from a multidose bottle creates a higher microbiological-control burden.

Is sugar-free lidocaine viscous a meaningful commercial opportunity?

Yes. A sugar-free formulation can support dental, institutional, and chronic oral-care positioning. The formulation must still address bitterness, osmolality, viscosity, and patient acceptability.

Can a new lidocaine viscous formulation receive patent protection?

Potentially. The strongest opportunities involve a specific and technically supported combination of excipients, rheology, taste masking, preservative control, packaging, or dose-limiting delivery. Broad claims covering standard lidocaine and conventional oral-liquid excipients are less likely to provide durable protection.

References

1. U.S. Food and Drug Administration. (2014). FDA recommends not using lidocaine to treat teething pain and requires new boxed warning. https://www.fda.gov/drugs/drug-safety-and-availability/fda-recommends-not-using-lidocaine-treat-teething-pain-and-requires-new-boxed-warning

2. DailyMed. (n.d.). Xylocaine viscous 2% lidocaine hydrochloride oral topical solution: Prescribing information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

4. U.S. Food and Drug Administration. (2018). Benzocaine topical products: Sprays, gels and liquids - risk of methemoglobinemia. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/benzocaine-topical-products-sprays-gels-and-liquids-risk-methemoglobinemia